Physician profile
Jacqueline Beer
NPI 1558448910
$11,462.68
in general payments reported to CMS, 2019-2025
37 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,604 · 2020: $355 · 2021: $1,483 · 2022: $1,852 · 2023: $2,012 · 2024: $1,802 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,964 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,963.84 |
| Education | $204.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,563.96 | 2019-2025 | Rinvoq, Skyrizi |
| Merz North America, INC. | $1,183.01 | 2019-2023 | |
| Janssen Biotech, INC. | $1,014.94 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $850.97 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $636.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $531.36 | 2019-2025 | |
| Lilly USA, LLC | $511.47 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $509.33 | 2019-2025 | |
| Ucb, INC. | $419.83 | 2021-2025 | Bimzelx |
| Incyte Corporation | $385.36 | 2021-2025 | Opzelura |
| Medimetriks Pharmaceuticals, INC. | $370.11 | 2019 | |
| Leo Pharma INC. | $337.37 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $322.25 | 2023-2024 | Vtama |
| Amgen INC. | $308.57 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $273.76 | 2019-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Beer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.